April 5 (Reuters) - Oncolytics Biotech Inc ONC.TO
* Oncolytics Biotech inc says Reolysin more than doubles overall survival in patients with mutated p53 metastatic breast cancer
* Oncolytics Biotech -patients with mutated p53 metastatic breast cancer saw a statistically significant improvement in median overall survival Source text for Eikon: ID:nPn3qW6BVa Further company coverage: ONC.TO